Clinical Trial · NCT00577629

Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins Lymphoma

Overview

The purpose of this study is to determine whether using high-dose chemotherapy, monoclonal antibodies, and targeted radioimmunotherapy will slow the progression of disease in patients with high-risk Non-Hodgkin's Lymphoma (NHL).

Sponsor

Duke University

Phase

Phase 2

Contacts

David Rizzieri, MD (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT00577629

Drug / Compound

tositumomab

Isotope(s):

Target(s):

cd20

Ligand Class: Antibodies

Eligibility

Inclusion

Meet staging studies and laboratory tests prior to induction, consolidation and radioimmunotherapy.
Untreated, biopsy proven B-cell non-Hodgkin's lymphoma

Exclusion

HIV-infection.
Patients with follicular lymphoma grade 1, 2 or 3A are not eligible for this trial.
Significant medical and/or psychiatric illness which may compromise planned treatment;
Pregnant or lactating;